1991
Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease.
Cedarbaum J, Leger G, Guttman M. Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease. Clinical Neuropharmacology 1991, 14: 330. PMID: 1913700, DOI: 10.1097/00002826-199108000-00005.Peer-Reviewed Original Research
1988
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Cedarbaum J, Kutt H, McDowell F. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988, 38: 533-6. PMID: 3352906, DOI: 10.1212/wnl.38.4.533.Peer-Reviewed Original ResearchConceptsDaily intakeRecent clinical trialsMean daily intakeTotal daily intakeLevodopa intakeStandard SinemetClinical responseLevodopa preparationsBrain uptakeClinical trialsPlasma concentrationsClinical significanceBlood samplingLevodopaTherapeutic efficacyMethyldopa levelsControlled-release formulationPatientsIntakeTime curveAUCSinemetLevelsTrials
1986
Effect of Supplemental Carbidopa on Bioavailability of l-Dopa.
Cedarbaum J, Kutt H, Dhar A, Watkins S, McDowell F. Effect of Supplemental Carbidopa on Bioavailability of l-Dopa. Clinical Neuropharmacology 1986, 9: 153. PMID: 3085927, DOI: 10.1097/00002826-198604000-00006.Peer-Reviewed Original Research